Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated Cytarabine Consolidation for Older AML Patients
NCT04914676Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by University of Florida. Primary endpoint: Duration of Neutropenia at 5 months. Started Mar 2022; status: terminated.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04914676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914676.